Randomized, Double-Blind, Placebo-Controlled Study of Modified Erzhi Granules in the Treatment of Menopause-Related Vulvovaginal Atrophy

Table 3

Vaginitis scores.

	groups	baseline	4 weeks	8 weeks	12 weeks	4 weeks after drug withdrawal	p1	p2	p3	p4
Vaginitis score	treatment group	4.50±1.57	2.68±0.99	1.91±0.97	1.41±0.85	2.09±1.02	<0.001	<0.001	<0.001	<0.001
	placebo group	4.58±1.57	4.63±1.54	4.58±1.61	4.63±1.54	4.58±1.64	0.710	1.000	0.650	1.000
	p	0.925	<0.001	<0.001	<0.001	<0.001
pain	treatment group	0.87±0.52	0.64±0.49	0.51±0.51	0.26±0.44	0.36±0.49	0.010	<0.001	<0.001	<0.001
	placebo group	0.94±0.63	0.97±0.65	0.97±0.65	0.94±0.63	1.00±0.68	0.320	0.320	1.000	0.480
	p	0.619	0.024	0.002	<0.001	<0.001
painful sexual intercourse	treatment group	1.18±0.73	1.09±0.68	1.00±0.62	0.95±0.58	0.95±0.58	0.160	0.050	0.030	0.030
	placebo group	1.26±0.81	1.32±0.82	1.37±0.83	1.37±0.83	1.32±0.82	0.320	0.160	0.160	0.320
	p	0.673	0.272	0.076	0.046	0.080
itching	treatment group	1.38±0.75	0.85±0.63	0.38±0.49	0.23±0.43	0.49±0.56	<0.001	<0.001	<0.001	<0.001
	placebo group	1.19±0.58	1.08±0.55	1.08±0.65	1.06±0.63	1.08±0.60	0.050	0.250	0.100	0.210
	p	0.276	0.086	<0.001	<0.001	<0.001
burning	treatment group	1.18±0.68	0.28±0.51	0.08±0.27	0.03±0.16	0.44±0.50	<0.001	<0.001	<0.001	<0.001
	placebo group	1.06±0.71	1.08±0.69	1.11±0.71	1.08±0.73	1.03±0.81	0.560	0.320	0.560	0.650
	p	0.472	<0.001	<0.001	<0.001	<0.001